Leerink Partners analyst Ami Fadia maintained a Hold rating on Endo International (NASDAQ:ENDP) on Sunday, setting a price target of $7, which is approximately 6.79% below the present share price of $7.51.
Fadia expects Endo International to post earnings per share (EPS) of -$0.33 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Endo International, with an average price target of $8.14.
The analysts price targets range from a high of $12 to a low of $5.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $634.86 million and a net profit of $72.47 million. The company's market cap is $1.73 billion.
According to TipRanks.com, Leerink Partners analyst Ami Fadia is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 6.7% and a 51.11% success rate.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.